Risk factor
Resilient to price shocks
Profitability factor
Strong margins and returns
About
Changzhou Qianhong Biopharma CO.,LTD operates as a key player in China's biopharmaceutical sector, specializing in the research, development, production, and distribution of biological drugs, with a core focus on enzyme and polysaccharide-based compounds. The company's product lineup features a variety of active pharmaceutical ingredients (APIs). These include a range of anticoagulants such as heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium, alongside pancreatin for digestive aid, asparaginase for antineoplastic applications, kallidinogenase kallikrein for treating microcirculation disorders, and heparinoid. Furthermore, Changzhou Qianhong provides ready-to-administer preparations, like pre-filled syringes of nadroparin calcium, enoxaparin sodium, and dalteparin sodium, all used as anticoagulants. It also supplies asparaginase injections for cancer treatment and heparin sodium injections to prevent blood clots. The company extends its reach through the export of its products internationally. Founded in 1971, Changzhou Qianhong Biopharma CO.,LTD maintains its headquarters in Changzhou, China.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV